This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Alden, C. L. Articles by Morris, D. L. Search for Related Content PubMed PubMed Citation Articles by Alden, C. L. Articles by Morris, D. L. Social Bookmarking                         What's this?

The Pathologist and Toxicologist in Pharmaceutical Product Discovery

Monsanto Life Sciences, St. Louis, Missouri 63167, clalde{at}monsanto.com.

John E. Sagartz

Monsanto Life Sciences, St. Louis, Missouri 63167

Peter F. Smith

Monsanto Life Sciences, Skokie, Illinois 60077

Alan G. Wilson

Monsanto Life Sciences, St. Louis, Missouri 63167

Roderick T. Bunch

Monsanto Life Sciences, Skokie, Illinois 60077

Dale L. Morris

Monsanto Life Sciences, St. Louis, Missouri 63167

Significant change is occurring in the drug discovery paradigm; many companies are utilizing dedicated groups from the toxicology/ pathology disciplines to support early stage activities. The goal is to improve the efficiency of the discovery process for selecting a successful clinical candidate. Toxicity can be predicted by leveraging molecular techniques via rapid high-throughput, low-resource in vitro and in vivo test systems. Several important activities help create a platform to support rapid development of a new molecular entity. The proceedings of this symposium provide excellent examples of these applied concepts in pharmaceutical research and development. Leading biopharmaceutical companies recognize that a competitive advantage can be maintained via rapid characterization of animal models, the cellular identification of therapeutic targets, and improved sensitivity of efficacy assessment. The participation of the molecular pathologist in this quest is evolving rapidly, as evidenced by the growing number of pathologists that interact with drug discovery organizations.

Key Words: Pathologist • toxicologist • pharmaceutical discovery • efficacy models

References

• Balwierz P. and Bunch T. (1998). An in situ micronucleus assay: Implications for drug discovery. Environ. Mol. Mutagen 31(suppl. 29): 3.
• Davila J. and Morris D. (1999). Analysis of cytochrome P450 and phase II conjugating enzyme expression in adult male rat hepatocytes. In Vitro Cell. Dev. Biol. 35: 1-11 (in press).[CrossRef]
• International Conference on Harmonisation (March 1995). Fed. Register 60(40): 11274-11275.
• Phillips J., Gibson W., Hard G., and Alden C. (1990). Survey of QSAR and in vitro approaches for developing non-animal methods to supersede the in vivo LD50 test. Food Chem. Toxicol. 28: 375-394.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]

Toxicologic Pathology, Vol. 27, No. 1, 104-106 (1999)
DOI: 10.1177/019262339902700119


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Alden, C. L. Articles by Morris, D. L. Search for Related Content PubMed PubMed Citation Articles by Alden, C. L. Articles by Morris, D. L. Social Bookmarking                         What's this?